Ghoshal Kaushik

CCO Kaushik Ghoshal sold 9,745 shares of RMD at $239.31 on 2025-03-10, reducing holdings by 50.1%

Kaushik Ghoshal, Chief Commercial Officer at ResMed, liquidated exactly half of his RMD holdings (from 19,470 to 9,725 shares) in a $2.3M sale on 2025-03-10 at $239.31—a price now 5.8% above the current $225.79. The sale occurred within a week of four prior sales on 2025-03-03 at the same ticker, suggesting a systematic reduction program. Examined against his cross-ticker track record across 7 prior sells, his sales have been well-timed 66.67% of the time with an average 90-day return of +4.3%, indicating his selling pattern has historically preceded or coincided with stock weakness. At RMD specifically, his single measurable prior sale (2024-10-11) shows mixed timing: +5.8% 30-day return but -1.0% 90-day return, demonstrating the inherent unpredictability of any single trade. The company's fundamentals remain sound—$1.3B quarterly revenue, $344.6M net income, and +11.0% annual growth—but the scale of this reduction (50% of prior holdings) warrants attention as a shift in the insider's position conviction at the current valuation.

ResMed CCO Kaushik Ghoshal sold 9,113 shares for $2,145,185.96 on 2025-03-03, reducing stake by 48.4%.

Kaushik Ghoshal, Chief Commercial Officer at ResMed, executed 4 separate sales totaling 9,113 shares for $2,145,185.96 at a blended average price of $235.40 on 2025-03-03, reducing his holdings from 18,838 shares to 9,725 shares (a 48.4% reduction). The sales occurred near the upper end of the 52-week range ($173.72–$257.65), approximately $4 above the current price of $231.48. At the same-ticker level, Ghoshal's prior 3 sales at RMD showed mixed timing outcomes: 2 of 3 were well-timed at the 90-day mark, but the most recent sale on 2024-10-11 posted a +5.8% 30-day return, suggesting the stock continued climbing immediately after. The current transaction's significance is tempered by ResMed's strong fundamentals (revenue $1,282,089,000.00, net income $344,622,000.00, P/E 27.23), though the substantial 48.4% reduction in personal holdings at a near-52-week-high price point warrants monitoring of subsequent quarterly disclosures and share price trajectory.

CCO Kaushik Ghoshal sells 4,260 RMD shares at $238.48; retains 21,788 shares post-transaction

Kaushik Ghoshal, Chief Commercial Officer at ResMed, executed an open-market sale of 4,260 shares at $238.48 on 2024-10-11, reducing his holdings by -16.4% from 26,048 shares to 21,788 shares. His prior two sales at RMD (2024-09-12 and 2024-08-12) showed mixed outcomes: the September sale occurred 30 days before a -4.8% decline, while the August sale was followed by a +16.8% 30-day return, yielding no consistent timing pattern at this ticker. Across his broader open-market history spanning multiple tickers, his 2 prior sells averaged a +6.0% 30-day return, suggesting stock price strength after his recent sales has been the norm. ResMed trades at a P/E of 32.50 on annual revenue growth of +11.0% and $300.5M net income, placing the stock near its 52-week high (currently -5.4% from $252.92 peak), so this sale occurs in a strong valuation context without macroeconomic duress. The transaction itself carries routine significance given the modest share count and the CCO's continued substantial position of 21,788 shares.

CCO Ghoshal sells 5,000 RMD shares at $252.56; stock now $248.93 near 52-week high, up 12.0% in 30 days

Ghoshal Kaushik, Chief Commercial Officer at ResMed, sold 5,000 shares (18.7% of his pre-transaction holdings) on 2024-09-12 at $252.56, reducing his stake to 21,788 shares. The transaction occurred near the stock's 52-week high of $252.92, with RMD currently trading at $248.93 and having appreciated 12.0% over the prior 30 days and 17.6% over 90 days. His single prior discretionary sale at RMD on 2024-08-12 achieved a 30-day return of +16.8%. The company's fundamentals remain solid with annual revenue growth of 11.0%, net income of $300,492,000.00, and a P/E of 33.82. While the sale size and timing near recent highs merit observation, the absence of a 90-day outcome for the prior August trade limits any confidence-based signal derivation from his historical accuracy at this ticker.

RMD President (SaaS) Ghoshal sold 10,000 shares at $216.60 (8/12); retains 13,032 shares post-sale

Ghoshal Kaushik, President of the SaaS Business at ResMed, sold 10,000 shares for $2,166,000.00, reducing his holdings by 43.4% to 13,032 shares. The sale occurred at $216.60, trading 1.5% below the 52-week high of $223.64, within the company's recent trading range. ResMed's fundamentals remain solid with Revenue $1,196,980,000.00 and Net income $300,492,000.00 in the latest quarter, with annual revenue growth of +11.0% and a market cap of $32,364,737,852.13. Without scheduled trade plan disclosure or explicit transaction justification in the filing, the sale represents a material reduction in stake from an executive officer, though the officer retains meaningful residual holdings.